MC916-C4, a cycloheximide-producing strain, by Umezawa et al.[2] Subsequent testing has shown its capabilities as an anticancer drug, antiprotozoal drug, and even possible uses in DNA fluorescence based assays.[3] Its activities against cancer warranted phase I testing of the drug.[4] More recently, in 1991, anthramycin derivatives, which are very similar to neothramycin, have been investigated for their ability to link DNA when dimerized. These compounds were tested using a fluorescence based assay.